retatrutide efficacy clinical trials and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 New GLP-3 drug significantly slashes

The 2024 joint scientific statement on nutrition and GLP-1 medications recommends involving a registered dietitian where appropriate, especially for people at risk of inadequate nutrient intake or muscle loss

Regulatory agencies like the FDA require strong safety databases for drugs that will be prescribed to millions of people, and a trial of this size provides the statistical power needed to detect both efficacy signals and uncommon adverse events

For a detailed head-to-head comparison, see our retatrutide vs tirzepatide comparison guide

Clin Ther (2012) 34:208290

Shelf-Stable Formula Vegan, non-GMO, gluten-free, dairy-free, and designed for stability without refrigeration

At that point, the amount of drug leaving your body is balanced by the amount youre adding with each new dose, creating a reliable therapeutic effect